Tiburio advances novel treatments for rare neuroendocrine tumors and rare endocrine diseases.
Tiburio is Cydan’s third orphan drug company, launched in January of 2019 with $31M in financing. Tiburio is a clinical stage biopharmaceutical company dedicated to advancing novel treatments for rare neuroendocrine tumors and rare endocrine diseases where there is significant patient need.
Tiburio’s pipeline consists of two clinical stage compounds, TBR-760 for the treatment of non-functioning pituitary adenoma (NFPA) and TBR-065 for additional rare endocrine diseases. Both of these compounds are novel dopamine-somatostin chimeric molecules. This unique class of chimeric compounds combines structural elements of both dopamine and somatostatin giving them the ability to bind and activate both receptors. Studies suggest that these chimeric compounds may facilitate physical interactions between dopamine and somatostatin receptors that results in enhanced activity, offering new potential for a variety of diseases with unmet need.
Tiburio is located in Technology Square in Cambridge, Mass. For more information, please visit www.tiburio.com.